Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers

Biomaterials

Volumn 34, Issue 3, 2013, Pages 746-755

  Huang, Zhen ^a   Yang, Yang ^a   Jiang, Yucui ^a   Shao, Juan ^a   Sun, Xulun ^a   Chen, Jiangning ^a   Dong, Lei ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Cationic polymers; Toll like receptor 4; Tumor associated macrophage

Indexed keywords

ANTI-TUMOR IMMUNE; ANTITUMOR IMMUNITY; CANCER IMMUNOTHERAPY; CATIONIC DEXTRAN; CATIONIC POLYMERS; CLINICAL TRIAL; IMMUNE STIMULATION; IMMUNOLOGICAL ACTIVITY; IN-VITRO; KNOCKOUT MICE; NK CELLS; NUCLEIC ACID DRUGS; POLYETHYLENEIMINE; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR ANGIOGENESIS; WILD TYPES;

DISEASES; DRUG DELIVERY; INTERFERONS; MACROPHAGES; MAMMALS; NUCLEIC ACIDS; TUMORS;

FUNCTIONAL POLYMERS;

BLOCKING ANTIBODY; DEXTRAN; INTERLEUKIN 12; METHOTREXATE; POLYETHYLENEIMINE; POLYMER; TOLL LIKE RECEPTOR 4;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; CATIONS; DEXTRANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENEIMINE; SARCOMA; TH1 CELLS; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 84868471869     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.062     Document Type: Article

References (39)

1. Williams D.F. On the mechanisms of biocompatibility. Biomaterials 2008, 29:2941-2953.
2. Uto T., Akagi T., Yoshinaga K., Toyama M., Akashi M., Baba M. The induction of innate and adaptive immunity by biodegradable poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 2011, 32:5206-5212.
3. Li C., Liu H., Sun Y., Wang H., Guo F., Rao S., et al. PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. J Mol Cell Biol 2009, 1:37-45.
4. Shokouhi B., Coban C., Hasirci V., Aydin E., Dhanasingh A., Shi N., et al. The role of multiple toll-like receptor signalling cascades on interactions between biomedical polymers and dendritic cells. Biomaterials 2010, 31:5759-5771.
5. De Smedt S.C., Demeester J., Hennink W.E. Cationic polymer based gene delivery systems. Pharm Res 2000, 17:113-126.
6. Chen H., Li P., Yin Y., Cai X., Huang Z., Chen J., et al. The promotion of type 1 T helper cell responses to cationic polymers in vivo via toll-like receptor-4 mediated IL-12 secretion. Biomaterials 2010, 31:8172-8180.
7. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
8. Blattman J.N., Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 2004, 305:200-205.
9. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
10. O'Sullivan C., Lewis C.E. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 1994, 172:229-235.
11. Eriksson F., Tsagozis P., Lundberg K., Parsa R., Mangsbo S.M., Persson M.A., et al. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J Immunol 2009, 182:3105-3111.
12. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005, 65:3437-3446.
13. Dong L., Xia S., Chen H., Chen J., Zhang J. Anti-arthritis activity of cationic materials. J Cell Mol Med 2010, 14:2015-2024.
14. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
15. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
16. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
17. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000, 164:762-767.
18. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
19. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
20. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612.
21. Chen J.J., Lin Y.C., Yao P.L., Yuan A., Chen H.Y., Shun C.T., et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005, 23:953-964.
22. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., et al. " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-1268.
23. Luo Y., Zhou H., Krueger J., Kaplan C., Lee S.H., Dolman C., et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006, 116:2132-2141.
24. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
25. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
26. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4:249-258.
27. Guha M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 2012, 11:503-505.
28. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:155-168.
29. Egilmez N.K., Jong Y.S., Sabel M.S., Jacob J.S., Mathiowitz E., Bankert R.B. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000, 60:3832-3837.
30. Barbera-Guillem E., Nyhus J.K., Wolford C.C., Friece C.R., Sampsel J.W. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002, 62:7042-7049.
31. Cubillos-Ruiz J.R., Engle X., Scarlett U.K., Martinez D., Barber A., Elgueta R., et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009, 119:2231-2244.
32. Geissmann F., Gordon S., Hume D.A., Mowat A.M., Randolph G.J. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010, 10:453-460.
33. Huang Z., Zhang Z., Jiang Y., Zhang D., Chen J., Dong L., et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release 2012, 158:286-292.
34. Pardoll D., Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004, 10:887-892.
35. Golab J., Zagozdzon R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Int J Mol Med 1999, 3:537-544.
36. Zent C.S., Smith B.J., Ballas Z.K., Wooldridge J.E., Link B.K., Call T.G., et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53:211-217.
37. Car B.D., Eng V.M., Lipman J.M., Anderson T.D. The toxicology of interleukin-12: a review. Toxicol Pathol 1999, 27:58-63.
38. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
39. Movahedi K., Schoonooghe S., Laoui D., Houbracken I., Waelput W., Breckpot K., et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012; Aug 3, 10.1158/0008-5472.CAN-11-2994 [Epub ahead of print].